2024
Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia
Hunter C, Bewersdorf J, Mendez L, Podoltsev N, Zeidan A, Eighmy W, Roeder H, Malinis M, Shallis R. Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia. Blood 2024, 144: 1480-1480. DOI: 10.1182/blood-2024-211250.Peer-Reviewed Original ResearchInvasive fungal infectionsAcute myeloid leukemiaAntifungal prophylaxisDiagnosed AMLDrug-drug interactionsTransaminase elevationVisual disturbancesRates of invasive fungal infectionsInvasive fungal infections incidenceBaseline ANCCD4 countMyeloid leukemiaAllogeneic stem cell transplantationAnti-fungal prophylaxisAcute myeloid leukemia diagnosisDuration of neutropeniaBaseline CD4 countLess-intensive therapyStem cell transplantationPatient baseline characteristicsSide effect profileCandida sppTriazole agentsWilcoxon rank sum testAntifungal voriconazoleRisk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia
Hunter C, Bewersdorf J, Mendez L, Podoltsev N, Zeidan A, Eighmy W, Roeder H, Malinis M, Shallis R. Risk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia. Blood 2024, 144: 4253. DOI: 10.1182/blood-2024-211426.Peer-Reviewed Original ResearchInvasive fungal infection diagnosisInvasive fungal infectionsAcute myeloid leukemiaInvasive Fungal Infection GroupAntifungal prophylaxis agentAntifungal prophylaxisCases of invasive fungal infectionsRates of invasive fungal infectionsFungal infectionsMyeloid leukemiaPrevent invasive fungal infectionsMycoses Study Group Education and Research ConsortiumRate of mortalityIFI patientsAllogeneic stem cell transplantationRisk factorsConsensus definitionAssociated with early mortalityNon-IFI groupSingle-gene mutationsPeriod of neutropeniaDays of neutropeniaAcute myeloid leukemia subtypesStem cell transplantationKaplan-Meier method
2023
2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed?
Perreault S, Schiffer M, Roeder H, McManus D, Topal J. 2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed? Open Forum Infectious Diseases 2023, 10: ofad500.2348. PMCID: PMC10678736, DOI: 10.1093/ofid/ofad500.2348.Peer-Reviewed Original ResearchInvasive fungal infectionsBreakthrough invasive fungal infectionsAntifungal prophylaxisFluconazole prophylaxisRisk factorsDay 75Conditioning regimenRisk patientsLower incidenceAllogeneic hematopoietic stem cell transplant patientsHistory of IFIRate of IFIHematopoietic stem cell transplant patientsHigh-intensity conditioning regimensStem cell transplant patientsFungal infectionsAnti-mold prophylaxisHigh-dose steroidsRoutine antifungal prophylaxisTacrolimus/sirolimusIntensity conditioning regimensHigh-risk patientsLow-risk patientsCell transplant patientsBreakthrough fungal infections
2022
Invasive Fungal Infections Are Underdiagnosed in Hospitalized Patients With Decompensated Cirrhosis: An Autopsy Study
SAFFO S, JAIN D, SANCHEZ H, GARCIA-TSAO G. Invasive Fungal Infections Are Underdiagnosed in Hospitalized Patients With Decompensated Cirrhosis: An Autopsy Study. Gastro Hep Advances 2022, 1: 803-806. PMID: 36160304, PMCID: PMC9497452, DOI: 10.1016/j.gastha.2022.05.015.Peer-Reviewed Original ResearchInvasive fungal infectionsDecompensated cirrhosisHospitalized patientsAutopsy studyFungal infectionsCirrhosisPatientsInfectionRectal screening for azole non‐susceptible Candida species in patients undergoing liver transplantation
Radcliffe C, Patel KK, Azar MM, Koff A, Belfield KD, Peaper DR, Topal JE, Malinis M. Rectal screening for azole non‐susceptible Candida species in patients undergoing liver transplantation. Transplant Infectious Disease 2022, 24: e13811. PMID: 35184347, DOI: 10.1111/tid.13811.Peer-Reviewed Original ResearchConceptsAppropriate antifungal prophylaxisAntifungal prophylaxisRisk factorsTransplant recipientsRectal swabsSolid organ transplant recipientsCommon invasive fungal infectionYale-New Haven HospitalDays of LTTime of LTLiver transplant recipientsOrgan transplant recipientsRetrospective chart reviewMore risk factorsMultiple risk factorsInvasive fungal infectionsNew Haven HospitalPrimary LTLiver transplantationAdult patientsChart reviewLT candidatesRectal screeningCandida infectionsMedian number
2021
Nocardiosis and elevated beta-d-glucan in solid organ transplant recipients
Ringer M, Radcliffe C, Kerantzas CA, Malinis M, Azar MM. Nocardiosis and elevated beta-d-glucan in solid organ transplant recipients. IDCases 2021, 26: e01322. PMID: 34786341, PMCID: PMC8577490, DOI: 10.1016/j.idcr.2021.e01322.Peer-Reviewed Case Reports and Technical NotesSOT recipientsBeta-d-glucan (BDG) testingSolid organ transplantation recipientsSolid organ transplant recipientsElevated BDG levelsOrgan transplant recipientsOrgan transplantation recipientsCases of nocardiosisFuture prospective studiesCases of patientsInvasive fungal infectionsBDG testingTransplant recipientsTransplantation recipientsClinical courseCase seriesProspective studyCase definitionIdentified causeElevated betaBDG levelsNocardiosisCausal associationFungal infectionsRecipientsIncidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib
Holowka T, Cheung H, Malinis M, Gan G, Deng Y, Perreault S, Isufi I, Azar MM. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. Journal Of Infection And Chemotherapy 2021, 27: 1700-1705. PMID: 34389223, DOI: 10.1016/j.jiac.2021.08.005.Peer-Reviewed Original ResearchConceptsInvasive fungal infectionsSerious infectionsRisk factorsHematologic malignanciesAdvanced ageMultivariate analysis risk factorsSmall molecule tyrosine kinase inhibitorsSingle tertiary care centerFungal infectionsConcurrent useCytotoxic agentsMolecule tyrosine kinase inhibitorsAnalysis risk factorsTertiary care centerTyrosine kinase inhibitorsElectronic medical recordsResult of infectionMost patientsClinical featuresInfected patientsMedical recordsCare centerImmune effectorsPatientsViral infectionSafety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Arrieta AC, Neely M, Day JC, Rheingold SR, Sue PK, Muller WJ, Danziger-Isakov LA, Chu J, Yildirim I, McComsey GA, Frangoul HA, Chen TK, Statler VA, Steinbach WJ, Yin DE, Hamed K, Jones ME, Lademacher C, Desai A, Micklus K, Phillips DL, Kovanda LL, Walsh TJ. Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00290-21. PMID: 34031051, PMCID: PMC8284446, DOI: 10.1128/aac.00290-21.Peer-Reviewed Original ResearchConceptsPhase 1 studyPediatric patientsIsavuconazonium sulfatePlasma drug exposureDrug exposureOral administrationImmunocompromised Pediatric PatientsNew triazole agentProdrug isavuconazonium sulfateTolerability of isavuconazoleBody mass indexPopulation PK modelInvasive fungal infectionsProbability of targetTarget rangeConcentration-time curveFirst-order inputMass indexPopulation pharmacokineticsStepwise covariate modelingTriazole agentsClinical dosePK parametersLinear eliminationPatients
2020
A Statewide Assessment of Antifungal Stewardship Activities in Acute-Care Hospitals in Connecticut
Bromberg R, Leung V, Maloney M, Paranandi A, Banach D. A Statewide Assessment of Antifungal Stewardship Activities in Acute-Care Hospitals in Connecticut. Infection Control And Hospital Epidemiology 2020, 41: s105-s105. DOI: 10.1017/ice.2020.609.Peer-Reviewed Original ResearchAcute care hospitalsInfectious disease consultationCandida bloodstream isolatesDisease consultationAntifungal susceptibility testingAntifungal therapyBloodstream isolatesConnecticut hospitalsCandidemia treatmentSusceptibility testingInstitutional guidelinesAntibiotic stewardship principlesCandida bloodstream infectionsDays of therapyEmpiric antifungal therapyInfectious disease physiciansInvasive fungal infectionsCDC core elementsAntifungal expenditureAntifungal utilizationOral conversionDisease physiciansHospitalized patientsProspective auditBloodstream infectionsUpdate on invasive fungal infections in the Middle Eastern and North African region
Osman M, Al Bikai A, Rafei R, Mallat H, Dabboussi F, Hamze M. Update on invasive fungal infections in the Middle Eastern and North African region. Brazilian Journal Of Microbiology 2020, 51: 1771-1789. PMID: 32623654, PMCID: PMC7335363, DOI: 10.1007/s42770-020-00325-x.Peer-Reviewed Original ResearchCutaneous Fusariosis in a Patient with Job’s (Hyper‐IgE) Syndrome
Altibi A, Sheth R, Battisha A, Kak V. Cutaneous Fusariosis in a Patient with Job’s (Hyper‐IgE) Syndrome. Case Reports In Infectious Diseases 2020, 2020: 3091806. PMID: 32607263, PMCID: PMC7315260, DOI: 10.1155/2020/3091806.Peer-Reviewed Original ResearchHyper-IgE syndromeInvasive fungal infectionsDiagnosis of hyper-IgE syndromePresence of cutaneous manifestationsPositive wound culturesAntifungal choiceFilamentous fungiAntifungal therapyFungal infectionsSystemic antifungalsImmunocompromised hostsOpportunistic infectionsRecurrent infectionsSurgical debridementWound culturesPunch biopsyCutaneous manifestationsFavorable outcomeAntimicrobial treatmentFusariosisWound debridementRisk factorsPatientsMultimodal approachInfection
2019
Factors influencing caspofungin plasma concentrations in kidney transplant patients with high incidence of invasive fungal infections
Yang Q, Zhang T, Zhao D, Zhang Y, Dong Y, Sun D, Du Q, Zheng J, Lu H, Dong Y. Factors influencing caspofungin plasma concentrations in kidney transplant patients with high incidence of invasive fungal infections. Journal Of Clinical Pharmacy And Therapeutics 2019, 45: 72-80. PMID: 31468555, DOI: 10.1111/jcpt.13026.Peer-Reviewed Original ResearchConceptsKidney transplant patientsInvasive fungal infectionsTransplant patientsConcomitant medicationsPlasma concentrationsContinuous renal replacement therapyFungal infectionsRenal replacement therapyUncontrolled observational studiesAntifungal prophylaxisKidney recipientsTrough concentrationsBaseline diseaseReplacement therapyObservational studyHealthy volunteersCyclosporine AProphylaxisHigh incidencePatientsMultivariate analysisMedicationsALB concentrationLiquid chromatography-tandem mass spectrometry methodCandida sppSirolimus‐associated pericardial effusion with cardiac tamponade and interstitial pneumonitis in a hematopoietic stem cell transplant recipient
Joo SJ, Yildirim I, Stenger EO, Anderson EJ. Sirolimus‐associated pericardial effusion with cardiac tamponade and interstitial pneumonitis in a hematopoietic stem cell transplant recipient. Pediatric Transplantation 2019, 23: e13425. PMID: 31012209, DOI: 10.1111/petr.13425.Peer-Reviewed Original ResearchConceptsHSCT patientsCardiac tamponadeInterstitial pneumonitisPericardial effusionAllogeneic hematopoietic stem cell transplant patientsHematopoietic stem cell transplant recipientsHematopoietic stem cell transplant patientsStem cell transplant patientsStem cell transplant recipientsAllogeneic HSCT patientsCell transplant recipientsLife-threatening complicationsCell transplant patientsTreatment of graftInvasive fungal infectionsGVHD prophylaxisHost diseaseTransplant patientsTransplant recipientsSirolimus useRapamycin inhibitorsPotent immunosuppressantPatientsFungal infectionsMammalian target
2015
Fungal Mycotic Aneurysm of the Internal Carotid Artery Associated with Sphenoid Sinusitis in an Immunocompromised Patient: A Case Report and Review of the Literature
Azar MM, Assi R, Patel N, Malinis MF. Fungal Mycotic Aneurysm of the Internal Carotid Artery Associated with Sphenoid Sinusitis in an Immunocompromised Patient: A Case Report and Review of the Literature. Mycopathologia 2015, 181: 425-433. PMID: 26687073, DOI: 10.1007/s11046-015-9975-1.Peer-Reviewed Case Reports and Technical NotesConceptsInternal carotid arteryFungal mycotic aneurysmsMycotic aneurysmSphenoid sinusitisICA aneurysmsSphenoid sinusEORTC/MSG criteriaInternal Carotid Artery AssociatedFungal sphenoid sinusitisLiposomal amphotericin B.Parent vessel sacrificeInvasive fungal infectionsDuration of antimicrobialsEffective antifungal therapyDevastating complicationSurgical debridementEndoscopic resectionAngioinvasive infectionVessel sacrificeCase reportAntifungal therapyCoil embolizationIdeal treatmentCavernous sinusCarotid artery
2013
Polymeric microparticles-based formulation for the eradication of cutaneous candidiasis: development and characterization
Kumar L, Verma S, Jamwal S, Vaidya S, Vaidya B. Polymeric microparticles-based formulation for the eradication of cutaneous candidiasis: development and characterization. Pharmaceutical Development And Technology 2013, 19: 318-325. PMID: 23560821, DOI: 10.3109/10837450.2013.778874.Peer-Reviewed Original ResearchConceptsCutaneous candidiasisVivo antifungal activity studiesFungal infectionsInvasive fungal infectionsMicrosphere gelSkin retention studyBetter therapeutic activitySystemic absorptionTopical applicationDrug accumulationGuinea pigsNovel drug delivery systemsTopical fungal infectionsTherapeutic activityCandidiasisAdverse effectsDermal penetrationInfectionSkinDermal deliveryConfocal microscopyDrug delivery systemsCarbopol 934Entrapment of drugDermal region
2006
Fatal Factitious Cushing’s Syndrome and Invasive Aspergillosis: Case Report and Review of Literature
Kansagara DL, Tetrault J, Hamill C, Moore C, Olson B. Fatal Factitious Cushing’s Syndrome and Invasive Aspergillosis: Case Report and Review of Literature. Endocrine Practice 2006, 12: 651-655. PMID: 17229661, DOI: 10.4158/ep.12.6.651.Peer-Reviewed Case Reports and Technical NotesConceptsFactitious Cushing's syndromeCushing's syndromeInvasive aspergillosisDiffuse pulmonary infiltratesUntreated Cushing's syndromeFatal septic shockInvasive pulmonary aspergillosisMechanism of immunosuppressionInvasive fungal infectionsHealth care providersReview of literaturePulmonary infiltratesFulminant infectionSeptic shockImmunologic aspectsPulmonary aspergillosisClinical findingsCase reportFatal conditionDifficult diagnosisAdrenal cortexTreatment considerationsFactitious illnessPatient's homeSyndrome
1999
Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option
Seropian S, Nadkarni R, Jillella A, Salloum E, Burtness B, Hu G, Zelterman D, Cooper D. Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplantation 1999, 23: 599-605. PMID: 10217191, DOI: 10.1038/sj.bmt.1701610.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareAntibiotic ProphylaxisAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDose-Response Relationship, DrugHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansLymphoma, Non-HodgkinMelphalanMiddle AgedNeutropeniaPodophyllotoxinRetrospective StudiesConceptsPeripheral blood progenitor cell transplantHigh-dose chemotherapyAbsolute neutrophil countProgenitor cell transplantCell transplantHodgkin's diseaseHodgkin's lymphomaHerpes simplex virus serologyHigh-dose BEAM chemotherapyGram-positive bacteremiaDuration of neutropeniaRisk of bacteremiaPeriod of neutropeniaMultivariate logistic regressionInvasive fungal infectionsRisk of developmentNumber of CD34Amphotericin therapyBEAM chemotherapyFebrile neutropeniaNeutropenic infectionOral ciprofloxacinWBC engraftmentProphylactic antibioticsCare visits
1985
Oral trimethoprim/sulfamethoxazole for prevention of bacterial infection during the induction phase of cancer chemotherapy in children.
Kovatch A, Wald E, Albo V, Prin W, Orlando S, Wollman M, Phebus C, Shapiro E. Oral trimethoprim/sulfamethoxazole for prevention of bacterial infection during the induction phase of cancer chemotherapy in children. 1985, 76: 754-60. PMID: 3903647, DOI: 10.1542/peds.76.5.754.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnti-Infective AgentsAntineoplastic AgentsBacterial InfectionsChildChild, PreschoolClinical Trials as TopicDouble-Blind MethodDrug CombinationsDrug Therapy, CombinationFemaleHumansInfantLeukemia, LymphoidLeukemia, Myeloid, AcuteMaleMicrobial Sensitivity TestsRandom AllocationSulfamethoxazoleTrimethoprimTrimethoprim, Sulfamethoxazole Drug CombinationConceptsTrimethoprim/sulfamethoxazoleOral trimethoprim/sulfamethoxazoleTrimethoprim/sulfamethoxazole groupFebrile episodesBacterial infectionsAcute leukemiaSolid tumorsPlacebo-controlled studyFrequency of bacteremiaInduction phaseInvasive fungal infectionsLife-table analysisGranulocytopenic childrenInduction chemotherapyReceiving placeboIntensive chemotherapyPlacebo groupOral thrushMean durationChemotherapyBacteremiaFungal infectionsOverall riskCancer chemotherapyInfection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply